Advances in Tuberculosis Diagnosis, Pathophysiology, Treatment, and Therapy Duration (2020–2025): An Umbrella Review of Systematic Reviews and Meta-Analyses
Abstract
Tuberculosis (TB) remains a major global health threat despite advances in prevention and care, particularly among immunocompromised individuals and those with HIV coinfection. This umbrella review of systematic reviews and meta-analyses (January 2020–December 2025 synthesizes recent evidence on TB pathophysiology, diagnosis, treatment, and therapy duration, with emphasis on machine learning/artificial intelligence (ML/AI) applications and vulnerable populations. We searched PubMed, Scopus, Web of Science, and EMBASE for systematic reviews and meta-analyses using terms related to TB pathophysiology, diagnosis, treatment, therapy duration, and immunocompromised management, including ML/AI applications. Inclusion criteria: English-language publications, focus on human studies, and restriction from January 2020 to December 2025. As this is an umbrella review of existing systematic reviews and metaanalyses, findings were synthesized narratively. No new pooled analyses, meta-analyses, or meta-regressions were performed. Quantitative estimates are reproduced as reported in the source meta-analyses and attributed to those sources. Of 2000 identified records, 75 were included after screening and eligibility assessment (see PRISMA flow diagram). Significant findings encompass a deeper comprehension of immune dynamics in pathophysiology, increased diagnostic precision through AI and molecular methodologies, safer rifamycin-based therapies, and shorter treatment regimens demonstrating…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Synthesis, In Vitro and In Silico Molecular Docking Studies of Novel Phthalimide–Pyrimidine Hybrid Analogues to Thalidomide as Potent Antitubercular Agents
- Exploring the inhibitory performance of expired moxifloxacin and norfloxacin on copper corrosion in saline environment
- Molecular investigation of antimicrobial peptides against Helicobacter pylori proteins using a peptide-protein docking approach
- Screening of novel narrow-spectrum benzofuroxan derivatives for the treatment of multidrug-resistant tuberculosis through in silico, in vitro, and in vivo approaches
- Synthesis, Characterization, Anticancer, Antioxidant, and In Silico Evaluation of Semicarbazides and Thiosemicarbazides
- Fast and accurate prediction of drug induced proarrhythmic risk with sex specific cardiac emulators
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.